Ramon Bataller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2931247/publications.pdf

Version: 2024-02-01

306 papers 28,519 citations

7568 77 h-index 162 g-index

324 all docs

324 docs citations

times ranked

324

24550 citing authors

#	Article	IF	Citations
1	Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation. Hepatology, 2023, 77, 159-175.	7.3	20
2	Coexistent Alcohol-Related Liver Disease and Alcohol-Related Pancreatitis: Analysis of a Large Health Care System Cohort. Digestive Diseases and Sciences, 2022, 67, 2543-2551.	2.3	2
3	Ductular reaction promotes intrahepatic angiogenesis through Slit2–Roundabout 1 signaling. Hepatology, 2022, 75, 353-368.	7. 3	20
4	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2022, 20, e289-e297.	4.4	17
5	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	3.7	33
6	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcoholâ€essociated hepatitis. Hepatology, 2022, 75, 968-982.	7. 3	3
7	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 45-59.	17.8	50
8	Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA. Journal of Clinical and Translational Hepatology, 2022, 10, 398-404.	1.4	5
9	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut, 2022, 71, 1856-1866.	12.1	17
10	Plasma angiopoietin 2 as a novel prognostic biomarker in alcohol-related cirrhosis and hepatitis. Liver Research, 2022, , .	1.4	0
11	Cigarette smoking and liver diseases. Journal of Hepatology, 2022, 77, 191-205.	3.7	40
12	Src kinase as a potential therapeutic target in nonâ€alcoholic and alcoholic steatohepatitis. Clinical and Translational Discovery, 2022, 2, .	0.5	1
13	Effect of rifaximin on infections, acuteâ€onâ€chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAâ€AH). Liver International, 2022, 42, 1109-1120.	3.9	20
14	Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 Pandemic. Clinical Gastroenterology and Hepatology, 2022, 20, 2142-2144.e2.	4.4	38
15	The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. The Lancet Gastroenterology and Hepatology, 2022, 7, 552-559.	8.1	25
16	Value of pilot studies in alcoholâ€associated hepatitis. Liver International, 2022, 42, 1697-1697.	3.9	0
17	Galectinâ€3 is overexpressed in advanced cirrhosis and predicts postâ€liver transplant infectious complications. Liver International, 2022, 42, 2260-2273.	3.9	10
18	A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies. Metabolites, 2022, 12, 528.	2.9	3

#	Article	IF	CITATIONS
19	Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure. Journal of Clinical Investigation, 2022, 132, .	8.2	23
20	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology, 2021, 73, 571-585.	7.3	56
21	Introducing ELâ€FIT (Exercise and Liver FITness): A Smartphone App to Prehabilitate and Monitor Liver Transplant Candidates. Liver Transplantation, 2021, 27, 502-512.	2.4	33
22	Integrated Multiomics Reveals Glucose Use Reprogramming and Identifies a Novel Hexokinase in Alcoholic Hepatitis. Gastroenterology, 2021, 160, 1725-1740.e2.	1.3	35
23	Serum Acylcarnitines Associated with High Short-Term Mortality in Patients with Alcoholic Hepatitis. Biomolecules, 2021, 11, 281.	4.0	7
24	Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases. BMC Medicine, 2021, 19, 39.	5.5	8
25	An Experimental DUAL Model of Advanced Liver Damage. Hepatology Communications, 2021, 5, 1051-1068.	4.3	11
26	Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis. JCI Insight, 2021, 6, .	5.0	5
27	Portal vein thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis. Transplant International, 2021, 34, 1105-1122.	1.6	6
28	Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis. Hepatology International, 2021, 15, 1006-1017.	4.2	6
29	Myeloid Endoplasmic Reticulum Resident Chaperone GP96 Facilitates Inflammation and Steatosis in Alcoholâ€Associated Liver Disease. Hepatology Communications, 2021, 5, 1165-1182.	4.3	10
30	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. Journal of Hepatology, 2021, 75, 1026-1033.	3.7	59
31	Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nature Communications, 2021, 12, 4560.	12.8	37
32	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcoholâ€Associated Hepatitis. Liver Transplantation, 2021, 27, 1382-1391.	2.4	4
33	Impact of Public Health Policies on Alcoholâ€Associated Liver Disease in Latin America: An Ecological Multinational Study. Hepatology, 2021, 74, 2478-2490.	7.3	27
34	Moderate Alcoholic Hepatitis. Clinics in Liver Disease, 2021, 25, 537-555.	2.1	10
35	Alcoholic Hepatitis. Clinical Liver Disease, 2021, 18, 90-95.	2.1	6
36	Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis. Journal of Hepatology, 2021, 75, 912-923.	3.7	34

3

#	Article	IF	CITATIONS
37	Socioeconomic inequalities in the incidence of alcohol-related liver disease in the Latin American context. Lancet Regional Health - Europe, The, 2021, 10, 100229.	5 . 6	3
38	CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nature Communications, 2021, 12, 7172.	12.8	22
39	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	7.3	151
40	Hepatocyte–stellate cell synapse in alcohol-induced steatosis: another role for endocannabinoids. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 5-6.	17.8	3
41	A Novel Mouse Model of Acuteâ€onâ€Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 2020, 44, 87-101.	2.4	8
42	Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century. American Journal of Gastroenterology, 2020, 115, 79-87.	0.4	47
43	Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. Hepatology, 2020, 71, 2080-2092.	7.3	106
44	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	12.1	112
45	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Coâ€Metabolism in Patients With Alcoholic Hepatitis. Hepatology Communications, 2020, 4, 1168-1182.	4.3	22
46	Coexistence of alcohol-related pancreatitis and alcohol-related liver disease: A systematic review and meta-analysis. Pancreatology, 2020, 20, 1069-1077.	1.1	7
47	Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. Scientific Reports, 2020, 10, 15558.	3.3	30
48	Alcoholâ€Related Liver Disease in Latin America: Local Solutions for a Global Problem. Clinical Liver Disease, 2020, 16, 187-190.	2.1	11
49	Are We Really Taking Care of Alcoholâ€Related Liver Disease in Latin America?. Clinical Liver Disease, 2020, 16, 91-95.	2.1	11
50	Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH. Cells, 2020, 9, 1237.	4.1	13
51	Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11667-11673.	7.1	50
52	Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice. Journal of Lipid Research, 2020, 61, 983-994.	4.2	21
53	Reply. Hepatology, 2020, 72, 2239-2240.	7.3	0
54	Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. American Journal of Gastroenterology, 2020, 115, 398-405.	0.4	24

#	Article	IF	CITATIONS
55	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	7.3	74
56	Perturbations in Mitochondrial Dynamics Are Closely Involved in the Progression of Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2020, 44, 856-865.	2.4	21
57	Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Translational Gastroenterology and Hepatology, 2020, 5, 31-31.	3.0	25
58	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
59	IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. Journal of Hepatology, 2020, 72, 1052-1061.	3.7	35
60	Inhibition of HSP90 and Activation of HSF1 Diminish Macrophage NLRP3 Inflammasome Activity in Alcoholâ€Associated Liver Injury. Alcoholism: Clinical and Experimental Research, 2020, 44, 1300-1311.	2.4	33
61	Recent advances in alcoholic hepatitis. F1000Research, 2020, 9, 97.	1.6	12
62	Alcoholic-related liver disease: pathogenesis, management and future therapeutic developments. Revista Espanola De Enfermedades Digestivas, 2020, 112, 869-878.	0.3	10
63	Alcoholic Liver Disease, Management of. , 2020, , 56-63.		0
64	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nature Communications, 2019, 10, 3126.	12.8	124
65	From the Editor's desk…. Journal of Hepatology, 2019, 71, 231-234.	3.7	0
66	From the Editor's Desk…. Journal of Hepatology, 2019, 71, 853-855.	3.7	0
67	Public health policies and alcohol-related liver disease. JHEP Reports, 2019, 1, 403-413.	4.9	33
68	From the Editor's Desk…. Journal of Hepatology, 2019, 71, 641-644.	3.7	0
69	246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. Gastroenterology, 2019, 156, S-1186.	1.3	2
70	Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis. Digestive Diseases and Sciences, 2019, 64, 1460-1469.	2.3	36
71	From the Editor's desk…. Journal of Hepatology, 2019, 70, 1039-1042.	3.7	0
72	From the Editor's desk…. Journal of Hepatology, 2019, 71, 1-4.	3.7	0

#	Article	IF	CITATIONS
73	Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. Annals of Hepatology, 2019, 18, 144-154.	1.5	11
74	Deficient ILâ€6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis. Hepatology Communications, 2019, 3, 867-882.	4.3	24
75	From the Editor's desk…. Journal of Hepatology, 2019, 70, 583-586.	3.7	0
76	From the Editor's desk…. Journal of Hepatology, 2019, 70, 819-821.	3.7	0
77	Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clinical Gastroenterology and Hepatology, 2019, 17, 2320-2329.e12.	4.4	87
78	Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Annals of Hepatology, 2019, 18, 518-535.	1.5	69
79	Identifying New Epigenetic Drivers of Liver Fibrosis. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 237-238.	4.5	4
80	From the Editor's desk Journal of Hepatology, 2019, 70, 335-338.	3.7	0
81	Response to Forrest et al American Journal of Gastroenterology, 2019, 114, 176-176.	0.4	0
82	Reduced Serum Sphingolipids Constitute a Molecular Signature of Malnutrition in Hospitalized Patients With Decompensated Cirrhosis. Clinical and Translational Gastroenterology, 2019, 10, e00013.	2.5	10
83	Alcoholic hepatitis masquerading as tumor infiltration: Reversibility after abstinence. Clinical Case Reports (discontinued), 2019, 7, 2174-2176.	0.5	0
84	Journal of Hepatology: The Home of Liver Research, 2015–2019. Journal of Hepatology, 2019, 71, 1065-1069.	3.7	1
85	From the Editor's Desk…. Journal of Hepatology, 2019, 71, 1061-1064.	3.7	0
86	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. GastroenterologÃa Y HepatologÃa (English Edition), 2019, 42, 657-676.	0.1	1
87	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	27.8	493
88	Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse. Journal of Psychosomatic Research, 2019, 116, 75-82.	2.6	13
89	Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. Hepatology, 2019, 69, 2180-2195.	7.3	52
90	Alcohol-related liver disease: Time for action. Journal of Hepatology, 2019, 70, 221-222.	3.7	26

#	Article	IF	Citations
91	Colder Weather and Fewer Sunlight Hours Increase Alcohol Consumption and Alcoholic Cirrhosis Worldwide. Hepatology, 2019, 69, 1916-1930.	7.3	34
92	Histopathological and Molecular Signatures of a Mouse Model of Acute-on-Chronic Alcoholic Liver Injury Demonstrate Concordance With Human Alcoholic Hepatitis. Toxicological Sciences, 2019, 170, 427-437.	3.1	15
93	Enfermedad hepática por alcohol. GuÃas de práctica clÃnica. Documento de consenso auspiciado por la AEEH. GastroenterologÃa Y HepatologÃa, 2019, 42, 657-676.	0.5	12
94	From the Editor's desk Journal of Hepatology, 2018, 68, 377-379.	3.7	0
95	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	3.7	144
96	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). GuÃa de práctica clÃnica. GastroenterologÃa Y HepatologÃa, 2018, 41, 328-349.	0.5	71
97	ACG Clinical Guideline: Alcoholic Liver Disease. American Journal of Gastroenterology, 2018, 113, 175-194.	0.4	530
98	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF- $1\hat{l}_{\pm}$ Transactivation in Steatohepatitis. Cell Metabolism, 2018, 27, 339-350.e3.	16.2	62
99	From the Editor's desk Journal of Hepatology, 2018, 68, 1-4.	3.7	8
100	Î ² -Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. Journal of Hepatology, 2018, 69, 687-696.	3.7	48
101	From the Editor's desk Journal of Hepatology, 2018, 68, 631-634.	3.7	0
102	Controversies in clinical trials for alcoholic hepatitis. Journal of Hepatology, 2018, 68, 586-592.	3.7	24
103	Pyroptosis by caspase11/4â€gasderminâ€D pathway in alcoholic hepatitis in mice and patients. Hepatology, 2018, 67, 1737-1753.	7.3	165
104	From the Editor's desk.…. Journal of Hepatology, 2018, 69, 1209-1212.	3.7	0
105	From the Editor's Desk…. Journal of Hepatology, 2018, 69, 759-761.	3.7	0
106	From the Editor's desk Journal of Hepatology, 2018, 69, 993-995.	3.7	0
107	Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis. Journal of Hepatology, 2018, 69, 1219-1220.	3.7	5
108	Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. Journal of Controlled Release, 2018, 288, 227-238.	9.9	37

#	Article	IF	Citations
109	A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis. Liver Transplantation, 2018, 24, 1655-1664.	2.4	41
110	From the Editor's desk Journal of Hepatology, 2018, 68, 1107-1109.	3.7	1
111	From the Editor's desk Journal of Hepatology, 2018, 69, 1-4.	3.7	74
112	From the Editor's desk Journal of Hepatology, 2018, 68, 869-872.	3.7	0
113	<scp>TLR</scp> 7â€letâ€7 Signaling Contributes to Ethanolâ€Induced Hepatic Inflammatory Response in Mice and in Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 2018, 42, 2107-2122.	2.4	41
114	Corrigendum to "From the Editor's Desk August 2018―[J Hepatol 69 (2018) 265–268]. Journal of Hepatology, 2018, 69, 987.	3.7	0
115	From the Editor's desk Journal of Hepatology, 2018, 69, 559-561.	3.7	0
116	Alcoholic liver disease. Nature Reviews Disease Primers, 2018, 4, 16.	30.5	660
117	From the Editor's desk Journal of Hepatology, 2018, 69, 265-268.	3.7	1
118	Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation. Liver International, 2017, 37, 290-298.	3.9	8
119	From the Editor's desk Journal of Hepatology, 2017, 66, 1-4.	3.7	12
120	From the Editor's desk Journal of Hepatology, 2017, 66, 263-266.	3.7	0
121	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology, 2017, 66, 555-563.	7.3	91
122	Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?. Hepatology, 2017, 65, 1758-1761.	7.3	5
123	Reply to: "Effect of abstinence on the prognosis of patients with alcoholic liver disease: A word of cautionâ€₁ Journal of Hepatology, 2017, 66, 1330-1331.	3.7	0
124	From the Editor's desk Journal of Hepatology, 2017, 66, 869-872.	3.7	0
125	From the Editor's desk Journal of Hepatology, 2017, 66, 1107-1110.	3.7	1
126	From the Editor's desk Journal of Hepatology, 2017, 67, 1-4.	3.7	5

#	Article	IF	CITATIONS
127	From the Editor's desk Journal of Hepatology, 2017, 66, 469-472.	3.7	O
128	From the Editor's desk Journal of Hepatology, 2017, 66, 671-674.	3.7	1
129	A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis. American Journal of Gastroenterology, 2017, 112, 306-315.	0.4	68
130	Reply to: "Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: Methodological issues of confounding and prediction models― Journal of Hepatology, 2017, 66, 865.	3.7	1
131	From the Editor's desk Journal of Hepatology, 2017, 67, 659-662.	3.7	0
132	From the Editor's desk Journal of Hepatology, 2017, 67, 889-892.	3.7	0
133	From the Editor's desk Journal of Hepatology, 2017, 67, 437-440.	3.7	0
134	Epigenetics in Liver Fibrosis. Seminars in Liver Disease, 2017, 37, 219-230.	3.6	19
135	Binge drinking as a risk factor for advanced alcoholic liver disease. Liver International, 2017, 37, 1281-1283.	3.9	33
136	From the Editor's desk Journal of Hepatology, 2017, 67, 207-210.	3.7	0
137	Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open, 2017, 7, e013620.	1.9	36
138	From the Editor's desk Journal of Hepatology, 2017, 67, 1125-1128.	3.7	0
139	Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on longâ€term survival. Hepatology, 2017, 66, 1842-1853.	7.3	119
140	Human germline hedgehog pathway mutations predispose to fatty liver. Journal of Hepatology, 2017, 67, 809-817.	3.7	24
141	Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients. Journal of Hepatology, 2017, 67, 1018-1025.	3.7	48
142	Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. Journal of Hepatology, 2017, 66, 610-618.	3.7	195
143	Pathophysiology and Management of Alcoholic Liver Disease: Update 2016. Gut and Liver, 2017, 11, 173-188.	2.9	167
144	Role of MIF in Hepatic Inflammatory Diseases and Fibrosis. , 2017, , 109-134.		3

#	Article	IF	CITATIONS
145	Intestinal fungi contribute to development of alcoholic liver disease. Journal of Clinical Investigation, 2017, 127, 2829-2841.	8.2	336
146	Liver Transplantation for Alcoholic Liver Disease. Transplantation, 2016, 100, 981-987.	1.0	65
147	Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. Journal of Hepatology, 2016, 65, 998-1005.	3.7	84
148	Alcoholic hepatitis: Translational approaches to develop targeted therapies. Hepatology, 2016, 64, 1343-1355.	7.3	91
149	Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a metaâ€analysis of randomized trials. Liver International, 2016, 36, 721-728.	3.9	74
150	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut, 2016, 65, 1535-1545.	12.1	103
151	LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Scientific Reports, 2016, 6, 35610.	3.3	25
152	From the Editor's desk Journal of Hepatology, 2016, 65, 1073-1076.	3.7	0
153	From the Editor's desk Journal of Hepatology, 2016, 64, 1199-1202.	3.7	0
154	From the Editor's desk Journal of Hepatology, 2016, 64, 759-762.	3.7	0
155	New therapeutic targets in alcoholic hepatitis. Hepatology International, 2016, 10, 538-552.	4.2	21
156	Pathogenesis and Management of Alcoholic Liver Disease. Digestive Diseases, 2016, 34, 347-355.	1.9	47
157	From the Editor's desk Journal of Hepatology, 2016, 65, 1-4.	3.7	2
158	Biomarkers for monitoring alcohol use. Clinical Liver Disease, 2016, 8, 59-63.	2.1	38
159	From the Editor's desk…. Journal of Hepatology, 2016, 65, 457-461.	3.7	1
160	From the Editor's desk Journal of Hepatology, 2016, 65, 233-236.	3.7	0
161	A mouse model of alcoholic liver fibrosis-associated acute kidney injury identifies key molecular pathways. Toxicology and Applied Pharmacology, 2016, 310, 129-139.	2.8	14
162	Alcoholic hepatitis: should we combine old drugs for better results?. Hepatology International, 2016, 10, 851-853.	4.2	1

#	Article	IF	CITATIONS
163	From the Editor's desk Journal of Hepatology, 2016, 65, 657-660.	3.7	O
164	From the Editor's desk Journal of Hepatology, 2016, 65, 869-872.	3.7	0
165	From the Editor's desk Journal of Hepatology, 2016, 64, 1-4.	3.7	7
166	Reply. Hepatology, 2016, 64, 680-681.	7.3	0
167	From the Editor's desk Journal of Hepatology, 2016, 64, 991-995.	3.7	0
168	Diagnostic Approaches and Clinical End Points of Treatment in Alcoholic Liver Disease., 2016,, 195-209.		1
169	From the Editor's desk Journal of Hepatology, 2016, 64, 253-256.	3.7	0
170	From the Editor's desk Journal of Hepatology, 2016, 64, 527-531.	3.7	0
171	Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology, 2016, 150, 785-790.	1.3	387
172	New UK alcohol guidelines and Dry January: enough to give up boozing?. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 191-192.	17.8	5
173	Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. Gut, 2016, 65, 840-851.	12.1	14
174	ÂAlcoholic hepatitis: How far are we and where are we going?. Annals of Hepatology, 2016, 15, 463-73.	1.5	8
175	From the Editor's desk Journal of Hepatology, 2015, 63, 1-4.	3.7	3
176	From the Editor's desk…. Journal of Hepatology, 2015, 63, 775-777.	3.7	0
177	From the Editor's desk Journal of Hepatology, 2015, 63, 1057-1061.	3.7	0
178	From the Editor's desk Journal of Hepatology, 2015, 63, 1299-1302.	3.7	0
179	From the Editor's desk…. Journal of Hepatology, 2015, 62, 991-994.	3.7	0
180	Chemokine Receptor Ccr6 Deficiency Alters Hepatic Inflammatory Cell Recruitment and Promotes Liver Inflammation and Fibrosis. PLoS ONE, 2015, 10, e0145147.	2.5	19

#	Article	IF	CITATIONS
181	Liver Fibrosis in Alcoholic Liver Disease. Seminars in Liver Disease, 2015, 35, 146-156.	3.6	93
182	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology, 2015, 62, 762-772.	7.3	230
183	From the Editor's desk Journal of Hepatology, 2015, 62, 1221-1224.	3.7	0
184	Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans. Gastroenterology, 2015, 149, 1030-1041.e6.	1.3	114
185	Trends in the management and burden of alcoholic liver disease. Journal of Hepatology, 2015, 62, S38-S46.	3.7	254
186	Identifying Molecular Targets to Improve Immune Function in Alcoholic Hepatitis. Gastroenterology, 2015, 148, 498-501.	1.3	12
187	Liver Fibrosis. Seminars in Liver Disease, 2015, 35, 095-096.	3.6	10
188	Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut, 2015, 64, 1949-1960.	12.1	137
189	Alcoholic liver disease: Clinical and translational research. Experimental and Molecular Pathology, 2015, 99, 596-610.	2.1	36
190	From the Editor's desk Journal of Hepatology, 2015, 63, 537-539.	3.7	0
190 191	From the Editor's desk Journal of Hepatology, 2015, 63, 537-539. Overexpression of angiopoietinâ€2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392.	3.7	0 31
	Overexpression of angiopoietinâ€2 in rats and patients with liver fibrosis. Therapeutic consequences of		
191	Overexpression of angiopoietinâ€2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392. Molecular interplay between î"5ſi"6 desaturases and long-chain fatty acids in the pathogenesis of	3.9	31
191 192	Overexpression of angiopoietin†in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392. Molecular interplay between î"5ſi"6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2014, 63, 344-355. Deletion of SIRT1 From Hepatocytes in Mice Disrupts Lipin-1 Signaling and Aggravates Alcoholic Fatty	3.9 12.1	107
191 192 193	Overexpression of angiopoietinâ€2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392. Molecular interplay between î"5ſi"6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2014, 63, 344-355. Deletion of SIRT1 From Hepatocytes in Mice Disrupts Lipin-1 Signaling and Aggravates Alcoholic Fatty Liver. Gastroenterology, 2014, 146, 801-811. Paracentesis Is Associated With Reduced Mortality in Patients Hospitalized With Cirrhosis and	3.9 12.1 1.3	31 107 167
191 192 193	Overexpression of angiopoietinâ€2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392. Molecular interplay between Δ5ſĨ"6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2014, 63, 344-355. Deletion of SIRT1 From Hepatocytes in Mice Disrupts Lipin-1 Signaling and Aggravates Alcoholic Fatty Liver. Gastroenterology, 2014, 146, 801-811. Paracentesis Is Associated With Reduced Mortality in Patients Hospitalized With Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2014, 12, 496-503.e1.	3.9 12.1 1.3 4.4	31 107 167 77
191 192 193 194	Overexpression of angiopoietinâ 2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392. Molecular interplay between î*5 î*6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2014, 63, 344-355. Deletion of SIRT1 From Hepatocytes in Mice Disrupts Lipin-1 Signaling and Aggravates Alcoholic Fatty Liver. Gastroenterology, 2014, 146, 801-811. Paracentesis Is Associated With Reduced Mortality in Patients Hospitalized With Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2014, 12, 496-503.e1. Role of NADPH Oxidases in Liver Fibrosis. Antioxidants and Redox Signaling, 2014, 20, 2854-2872. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and	3.9 12.1 1.3 4.4	31 107 167 77

#	Article	IF	Citations
199	A Histologic Scoring System for Prognosis of Patients With AlcoholicÂHepatitis. Gastroenterology, 2014, 146, 1231-1239.e6.	1.3	353
200	Alcoholic hepatitis: Prognosis and treatment. GastroenterologÃa Y HepatologÃa, 2014, 37, 262-268.	0.5	23
201	Identifying Molecular Factors That Contribute to Resolution of Liver Fibrosis. Gastroenterology, 2014, 146, 1160-1164.	1.3	34
202	Lack of the Matricellular Protein SPARC (Secreted Protein, Acidic and Rich in Cysteine) Attenuates Liver Fibrogenesis in Mice. PLoS ONE, 2013, 8, e54962.	2.5	43
203	Alcoholic liver disease: Pathogenesis, management, and novel targets for therapy. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 77-84.	2.8	196
204	Molecular Mechanisms of Fibrosis-Associated Promotion of Liver Carcinogenesis. Toxicological Sciences, 2013, 132, 53-63.	3.1	84
205	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology, 2013, 58, 1742-1756.	7.3	87
206	Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut, 2013, 62, 452-460.	12.1	167
207	Alcohol and toxicity. Journal of Hepatology, 2013, 59, 387-388.	3.7	59
208	ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. Journal of Hepatology, 2013, 59, 805-813.	3.7	89
209	Semaphorin 7A Contributes to TGF-β–Mediated Liver Fibrogenesis. American Journal of Pathology, 2013, 183, 820-830.	3.8	46
210	Reply to: "The autophagic response to alcohol toxicity: The missing layer― Journal of Hepatology, 2013, 59, 399-400.	3.7	2
211	Dissecting the role of CB1 receptors on chronic liver diseases. Gut, 2013, 62, 957-958.	12.1	4
212	<i>Actin-binding proteins as molecular targets to modulate hepatic stellate cell proliferation ⟨i⟩. Focus on "MARCKS actin-binding capacity mediates actin filament assembly during mitosis in human hepatic stellate cells― American Journal of Physiology - Cell Physiology, 2012, 303, C355-C356.</i>	4.6	5
213	Detecting alcohol intake in patients with ALD. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 432-434.	17.8	5
214	Fueling fibrosis in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14293-14294.	7.1	16
215	Acute Kidney Injury Is an Early Predictor of Mortality for Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2012, 10, 65-71.e3.	4.4	155
216	Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice. Gastroenterology, 2012, 142, 1218-1228.e1.	1.3	155

#	Article	IF	CITATIONS
217	Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. Annals of Hepatology, 2012, 11, 213-221.	1.5	28
218	Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases. Annals of Hepatology, 2012, 11, 399-403.	1.5	10
219	Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology, 2012, 55, 1931-1941.	7.3	177
220	Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4. Cancer Cell, 2012, 21, 504-516.	16.8	1,051
221	Readthrough Acetylcholinesterase Is Increased in Human Liver Cirrhosis. PLoS ONE, 2012, 7, e44598.	2.5	25
222	Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases. Annals of Hepatology, 2012, 11, 399-403.	1.5	4
223	Alcoholic liver disease: pathogenesis and new targets for therapy. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 491-501.	17.8	241
224	Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterology, 2011, 141, 1572-1585.	1.3	1,544
225	The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis. American Journal of Gastroenterology, 2011, 106, 1472-1480.	0.4	33
226	Platelet-derived chemokines: New targets to treat liver fibrosis. Journal of Hepatology, 2011, 54, 581-583.	3.7	5
227	RANTES antagonism: A promising approach to treat chronic liver diseases. Journal of Hepatology, 2011, 55, 936-938.	3.7	17
228	Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut, 2011, 60, 1404-1411.	12.1	60
229	Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology, 2011, 53, 1629-1640.	7.3	78
230	Fibrosis in alcoholic and nonalcoholic steatohepatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 231-244.	2.4	63
231	Acute Pylephlebitis Following Gastrointestinal Infection: An Unrecognized Cause of Septic Shock. Southern Medical Journal, 2010, 103, 956-959.	0.7	7
232	Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology, 2010, 51, NA-NA.	7.3	96
233	Chrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology, 2010, 51, 974-985.	7.3	141
234	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology, 2010, 51, 1567-1576.	7.3	117

#	Article	IF	Citations
235	Reply: Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease. Hepatology, 2010, 52, 391-392.	7.3	1
236	Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3. Hepatology, 2010, 52, 1291-1300.	7.3	364
237	Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver International, 2010, 30, 31-41.	3.9	44
238	The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis. Gut, 2010, 59, 943-952.	12.1	9
239	Apelin Mediates the Induction of Profibrogenic Genes in Human Hepatic Stellate Cells. Endocrinology, 2010, 151, 5306-5314.	2.8	58
240	Cigarette smoking and chronic liver diseases. Gut, 2010, 59, 1159-1162.	12.1	84
241	Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition. Gastroenterology, 2010, 138, 347-359.	1.3	195
242	Acidic Sphingomyelinase Controls Hepatic Stellate Cell Activation and in Vivo Liver Fibrogenesis. American Journal of Pathology, 2010, 177, 1214-1224.	3.8	78
243	Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. American Journal of Physiology - Renal Physiology, 2009, 297, G726-G734.	3.4	110
244	Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. Gastroenterology, 2009, 136, 1639-1650.	1.3	197
245	Angiotensin II Activates lîºB Kinase Phosphorylation of RelA at Ser536 to Promote Myofibroblast Survival and Liver Fibrosis. Gastroenterology, 2009, 136, 2334-2344.e1.	1.3	117
246	Atorvastatin attenuates angiotensin Il-induced inflammatory actions in the liver. American Journal of Physiology - Renal Physiology, 2009, 296, G147-G156.	3.4	79
247	Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. American Journal of Physiology - Renal Physiology, 2009, 296, G553-G562.	3.4	66
248	Largeâ€conductance calciumâ€activated potassium channels modulate vascular tone in experimental cirrhosis. Liver International, 2008, 28, 566-573.	3.9	6
249	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. American Journal of Gastroenterology, 2008, 103, 2747-2756.	0.4	268
250	Reelin is overexpressed in the liver and plasma of bile duct ligated rats and its levels and glycosylation are altered in plasma of humans with cirrhosis. International Journal of Biochemistry and Cell Biology, 2008, 40, 766-775.	2.8	27
251	Cytokines and Renin-Angiotensin System Signaling in Hepatic Fibrosis. Clinics in Liver Disease, 2008, 12, 825-852.	2.1	7 5
252	Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity. Gastroenterology, 2007, 132, 687-697.	1.3	108

#	Article	IF	CITATIONS
253	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. Gastroenterology, 2007, 133, 2019-2028.	1.3	41
254	Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transplantation, 2007, 13, 1017-1027.	2.4	24
255	Up-Regulation of Myocardial L-Type Ca2+Channel in Chronic Alcoholic Subjects Without Cardiomyopathy. Alcoholism: Clinical and Experimental Research, 2007, 31, 1099-1105.	2.4	13
256	Resistin as an Intrahepatic Cytokine. American Journal of Pathology, 2006, 169, 2042-2053.	3.8	142
257	NADPH Oxidase in the Liver: Defensive, Offensive, or Fibrogenic?. Gastroenterology, 2006, 131, 272-275.	1.3	102
258	Time to ban smoking in patients with chronic liver diseases. Hepatology, 2006, 44, 1394-1396.	7.3	33
259	Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. American Journal of Physiology - Renal Physiology, 2006, 291, G877-G884.	3.4	54
260	Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology, 2005, 41, 1046-1055.	7.3	143
261	NF-κB activation in Kupffer cells after partial hepatectomy. American Journal of Physiology - Renal Physiology, 2005, 289, G530-G538.	3.4	48
262	The Role of p70S6K in Hepatic Stellate Cell Collagen Gene Expression and Cell Proliferation. Journal of Biological Chemistry, 2005, 280, 13374-13382.	3.4	85
263	Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. Journal of Hepatology, 2005, 43, 317-323.	3.7	105
264	Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. Journal of Hepatology, 2005, 43, 272-282.	3.7	78
265	Liver Fibrogenesis: A New Role for the Renin–Angiotensin System. Antioxidants and Redox Signaling, 2005, 7, 1346-1355.	5. 4	141
266	Liver fibrosis. Journal of Clinical Investigation, 2005, 115, 209-218.	8.2	4,210
267	TRAM2 Protein Interacts with Endoplasmic Reticulum Ca ²⁺ Pump Serca2b and Is Necessary for Collagen Type I Synthesis. Molecular and Cellular Biology, 2004, 24, 1758-1768.	2.3	69
268	A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology, 2004, 40, 1151-1159.	7.3	226
269	Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology, 2003, 37, 493-503.	7.3	298
270	Toll-Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology, 2003, 37, 1043-1055.	7.3	588

#	Article	IF	CITATIONS
271	Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology, 2003, 38, 452-459.	7.3	73
272	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology, 2003, 38, 919-929.	7.3	186
273	Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology, 2003, 125, 117-125.	1.3	317
274	Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. American Journal of Physiology - Renal Physiology, 2003, 285, G949-G958.	3.4	224
275	Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. American Journal of Physiology - Renal Physiology, 2003, 285, G642-G651.	3.4	119
276	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology, 2003, 38, 919-929.	7.3	88
277	NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. Journal of Clinical Investigation, 2003, 112, 1383-1394.	8.2	482
278	Increased plasma levels of neuropeptide Y in hepatorenal syndrome. Journal of Hepatology, 2002, 36, 349-355.	3.7	23
279	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	7.3	8
280	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	7.3	497
281	A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology, 2001, 34, 46-52.	3.7	225
282	Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. Journal of Hepatology, 2001, 34, 222-229.	3.7	24
283	Human myofibroblastic hepatic stellate cells express Ca2+-activated K+ channels that modulate the effects of endothelin-1 and nitric oxide. Journal of Hepatology, 2001, 35, 739-748.	3.7	27
284	In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology, 2001, 33, 956-962.	7.3	57
285	Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis. Seminars in Liver Disease, 2001, 21, 437-452.	3.6	444
286	Hepatorenal syndrome. Current Treatment Options in Gastroenterology, 2000, 3, 445-450.	0.8	63
287	MECHANISMS OF ASCITES FORMATION. Clinics in Liver Disease, 2000, 4, 447-465.	2.1	38
288	HEPATORENAL SYNDROME. Clinics in Liver Disease, 2000, 4, 487-507.	2.1	21

#	Article	IF	Citations
289	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology, 2000, 119, 794-805.	1.3	69
290	Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology, 2000, 118, 1149-1156.	1.3	459
291	Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology, 2000, 33, 43-48.	3.7	381
292	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. Journal of Hepatology, 2000, 33, 423-429.	3.7	29
293	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology, 1999, 30, 501-509.	7.3	30
294	Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology, 1998, 28, 39-44.	7.3	138
295	Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology, 1998, 114, 336-343.	1.3	103
296	Contraction of human hepatic stellate cells activated in culture: A role for voltage-operated calcium channels. Journal of Hepatology, 1998, 29, 398-408.	3.7	54
297	ESOPHAGEAL VARICEAL BLEEDING CAUSED BY HYPOPLASIA OF THE PORTAL VEIN IN A PATIENT WITH THE KLIPPEL-TRENAUNAY SYNDROME. American Journal of Gastroenterology, 1998, 93, 275-276.	0.4	14
298	Hepatorenal Syndrome. Seminars in Liver Disease, 1997, 17, 233-247.	3.6	83
299	Practical Recommendations for the Treatment of Ascites and Its Complications. Drugs, 1997, 54, 571-580.	10.9	21
300	Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. Journal of Hepatology, 1997, 26, 88-95.	3.7	109
301	Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. Journal of Hepatology, 1997, 27, 645-653.	3.7	59
302	Management of ascites in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 723-733.	2.8	8
303	Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. Journal of Hepatology, 1996, 25, 916-923.	3.7	57
304	Acute Eosinophilic Pneumonia Associated with Ranitidine. Journal of Clinical Gastroenterology, 1996, 23, 160-162.	2.2	5
305	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology, 1995, 22, 479-487.	7.3	41
306	Pathogenesis of Hepatic Fibrosis., 0,, 658-679.		2